pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

REGENERON PHARMACEUTICALS

USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participantsrecruitingn=2,000
  • phase1Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutationrecruitingn=52
  • phase1REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapyterminatedn=17
  • phase3Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitablerecruitingn=2,628
  • phase3A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphomaactive not recruitingn=733
  • phase2Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)not yet recruitingn=120
  • phase3A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgeryactive not recruitingn=1,564
  • phase2A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatmentactive not recruitingn=28
🐶 Hiring Signal
No open roles indexed yet — view REGENERON PHARMACEUTICALS jobs →

News

  • Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
    The go-ahead for Alnylam Pharmaceuticals–licensed Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
    biospace · 2d ago
  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
    biopharma_dive · 2d ago
  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    biopharma_dive · 5d ago
  • Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
    Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
    biospace · 8d ago
  • Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trial
    Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
    fiercebiotech · 8d ago
  • 10 companies hiring in New Jersey
    Looking for a biopharma job in New Jersey? Jobs on BioSpace increased year over year in October, and there are hundreds of open positions posted now.
    biospace · 9d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 11d ago
  • The top 12 companies hiring in biopharma now
    Average jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.
    biospace · 16d ago
  • Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
    biopharma_dive · 19d ago
  • Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
    Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…
    biospace · 22d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?